Zobrazeno 1 - 10
of 1 017
pro vyhledávání: '"Renal outcomes"'
Autor:
Jhih-Wei Dai, Yuan Lin, Xiu-Wei Li, Chin-Ju Tseng, Ming-Lung Tsai, Ning-I Yang, Ming-Jui Hung, Tien-Hsing Chen
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Given the limited head-to-head comparison of cardiovascular and renal outcomes between liraglutide and dulaglutide, our study aimed to investigate the clinical outcomes between dulaglutide and liraglutide in a real-world setting. In this new
Externí odkaz:
https://doaj.org/article/0c350cdf0b2a45288555c4b5ce1a8411
Publikováno v:
International Journal of Computational Intelligence Systems, Vol 17, Iss 1, Pp 1-14 (2024)
Abstract The current investigation aimed to develop a novel approach for risk prediction modeling of clinical outcomes in common diseases based on computational and human intelligence techniques with no a priori input on risk factors using real-world
Externí odkaz:
https://doaj.org/article/59050ac1ec924837b777ff49a67d2b41
Publikováno v:
BMC Nephrology, Vol 25, Iss 1, Pp 1-19 (2024)
Abstract Objective This meta-analysis was designed to investigate cardio-renal outcomes and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) as a therapeutic option among chronic kidney disease(CKD) patients with GFR
Externí odkaz:
https://doaj.org/article/b1ff9810811d4d2facaa010b990125fd
Autor:
Junichi Hoshino, Tomohiro Ohigashi, Ryoya Tsunoda, Yukiko Ito, Hirayasu Kai, Chie Saito, Hirokazu Okada, Ichiei Narita, Takashi Wada, Shoichi Maruyama, Ronald Pisoni, Roberto Pecoits-Filho, Kunihiro Yamagata
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract The association of physical activity with renal outcome and mortality in advanced chronic kidney disease (CKD; i.e., estimated glomerular filtration rate [eGFR]
Externí odkaz:
https://doaj.org/article/927a86feb15246ed937a975b5eaa4e98
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 16, Iss 1, Pp 1-11 (2024)
Abstract Background The triglyceride-glucose (TyG) index is a new and good biomarker of insulin resistance (IR). The prognostic utility of the TyG index for patients with type 2 diabetes mellitus (T2DM) remains uncertain. Our study seeks to elucidate
Externí odkaz:
https://doaj.org/article/9a08670aaa7e4bf7b6f461a6f4b86cf1
Publikováno v:
Renal Failure, Vol 46, Iss 1 (2024)
Aim Tripterygium wilfordii Hook F (TwHF) has been shown to substantially reduce proteinuria in patients with diabetic kidney disease (DKD); however, the effect of TwHF on renal outcomes in DKD remains unknown. Accordingly, we aimed to establish the e
Externí odkaz:
https://doaj.org/article/ca01d9417bd643a7927f6c14eeddc4a4
Autor:
Wenguang Lai, Yaxin Meng, Yang Zhou, Tingting Zhang, Baoyuan Zhang, Zhidong Huang, Zhiyong Gao
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
BackgroundAmong diabetes mellitus (DM) patients, stress hyperglycemia ratio (SHR) is a strong predictor of short- and long-term prognosis, and adverse cardiovascular events. However, whether SHR is associated with increased risk of presence and sever
Externí odkaz:
https://doaj.org/article/d02e943e8e8b425699303f26f992ef47
Autor:
Giuseppe Lisco, Olga Eugenia Disoteo, Vincenzo De Geronimo, Anna De Tullio, Vito Angelo Giagulli, Edoardo Guastamacchia, Giovanni De Pergola, Emilio Jirillo, Vincenzo Triggiani
Publikováno v:
Endocrines, Vol 5, Iss 1, Pp 72-86 (2024)
Background: Tirzepatide (TZP) is a once-weekly glucagon-like peptide 1 (GLP-1) and glucose-dependent-insulinotropic-polypeptide (GIP) receptor co-agonist approved for T2D. TZP provides promising evidence in improving glucose control and weight loss i
Externí odkaz:
https://doaj.org/article/cd4aec6ccfcc40fc8b15cb0ffd31880c
Autor:
Frederick Berro Rivera, Linnaeus Louisse A. Cruz, John Vincent Magalong, Jade Monica Marie J. Ruyeras, John Paul Aparece, Nathan Ross B. Bantayan, Kyla Lara-Breitinger, Martha Gulati
Publikováno v:
American Journal of Preventive Cardiology, Vol 18, Iss , Pp 100679- (2024)
Background: Multiple cardiovascular outcomes trials (CVOTs) have shown the efficacy of GLP-1RAs in reducing major adverse cardiovascular events (MACEs) for high-risk patients. However, some CVOTs failed to demonstrate cardiovascular benefits. Objecti
Externí odkaz:
https://doaj.org/article/ddaeeef737334d64a0255d15e73a22cc
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.